PLX3397, a CSFR1 inhibitor, has been extensively studied for its role in reducing TAM recruitment and reprogramming of these cells,[37, 38] particularly when combined with other immunotherapies.[39] In thyroid cancer, the effects of CSF1R inhibition by PLX3397 and inhibition of Spp1 have been noted[40]; however, the specific signaling pathways remain to be elucidated. Here, SPP1 is linked to thyroid gland carcinoma.